Full formMedical & Health
EGFRstands forEpidermal Growth Factor Receptor
Full Form of EGFR
What is EGFR?
EGFR (Epidermal Growth Factor Receptor) is a transmembrane protein receptor found on the surface of certain types of cells. When activated by growth factors, it triggers a signaling cascade that promotes cell growth, division, and survival. In the context of India, EGFR is a critical biomarker and therapeutic target in oncology, particularly for non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancers. The receptor is often mutated or overexpressed in various tumors, making it a key focus for targeted therapies such as tyrosine kinase inhibitors (gefitinib, erlotinib) and monoclonal antibodies (cetuximab, panitumumab). These treatments are widely used in Indian cancer hospitals and research institutes, especially as part of precision medicine initiatives. EGFR testing is routinely performed in Indian diagnostic labs to guide therapy selection, and the National Cancer Grid of India has incorporated EGFR mutation testing into standard protocols. For students and medical professionals, EGFR is a central topic in oncology, biochemistry, and molecular biology exams, including NEET PG, AIIMS, and USMLE. Understanding EGFR signaling pathways and mutation types (exon 19 deletions, L858R point mutation) is essential for clinical practice and research in India's growing cancer care landscape.
EGFR का फुल फॉर्म
एपिडर्मल ग्रोथ फैक्टर रिसेप्टर
Example
The oncologist recommended EGFR mutation testing before prescribing gefitinib for the lung cancer patient.
EGFR — frequently asked questions
What is the full form of EGFR?
The full form of EGFR is Epidermal Growth Factor Receptor, a protein on cell surfaces that regulates growth and division.
Why is EGFR important in cancer treatment in India?
EGFR mutations are common in Indian lung cancer patients, so testing guides the use of targeted drugs like gefitinib, improving outcomes.
What is the difference between EGFR and HER2?
EGFR (ErbB1) and HER2 (ErbB2) are both receptors in the same family, but HER2 does not bind directly to growth factors and is often tested in breast cancer.